Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case By Henry P Yang on Wednesday, March 01, 2023 article 3(a) article 3(c) patents royalty pharma SPC supplementary protection certificates Sweden Teva +
New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel) By Dr Rose Hughes on Monday, March 07, 2022 article 3(a) article 3(c) patents Rose Hughes royalty pharma SPC supplementary protection certificates +
The SPC alphabet: Are combination product SPCs precluded by Article 3(a), (c) and/or (d)? By Dr Rose Hughes on Monday, December 13, 2021 article 3(a) article 3(c) Article 3(d) patents Rose Hughes royalty pharma Santen SPC supplementary protection certificates +
Intellectual Property Challenges in the Bio-Pharmaceutical Field By Mike Mireles on Wednesday, May 04, 2016 biotechnology couzzo speed technologies dri capital inter partes review myriad patents pharmaceuticals price regulation royalty pharma securitization +